1. Pink Sheet
  2. >>Geography
  3. >>Europe

New EU Clinical Trial System Has Implications For Wider Study Operations

 
• By Vibha Sharma

Companies readying themselves for the upcoming implementation of the EU Clinical Trial Regulation should think beyond its obvious stated aim of harmonizing the submission and evaluation of trial applications. The regulation, which will be implemented via a new portal, has the potential to affect several business dimensions.

Clinical trial
EU CT Portal Will Result In Major Changes To Clinical Trial Conduct • Source: Shutterstock

The European Medicines Agency’s new Clinical Trial Information System (CTIS) may be an EU-centric tool designed to implement specific provisions of the EU Clinical Trial Regulation, but companies should be mindful of the combined impact of these provisions on their overall study operations.

The CTR – and its implementation via the CTIS portal – will not just affect company processes relating to the submission of clinical trial dossiers in the EU

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.